Studies on pure red cell aplasia. VI. Development of two-stage erythroblast cytotoxicity method and role of complement.
D000085:Acetates / Q000494:pharmacology; D000741:Anemia, Aplastic / Q000276:immunology* / Q000628:therapy; D001803:Blood Transfusion; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D002848:Chromatography, DEAE-Cellulose; D002859:Chromium Isotopes; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins; D003601:Cytotoxicity Tests, Immunologic; D004912:Erythrocytes / Q000276:immunology*; D004921:Erythropoietin; D005615:Freezing; D006018:Glycols / Q000494:pharmacology; D006358:Hot Temperature; D006801:Humans; D007503:Iron Isotopes; D007553:Isotope Labeling; D008722:Methods; D013498:Suramin / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology; D005719:gamma-Globulins / Q000302:isolation & purification
D000085:Acetates; D002859:Chromium Isotopes; D003169:Complement Inactivator Proteins; D006018:Glycols; D007503:Iron Isotopes; D005719:gamma-Globulins; D004921:Erythropoietin; D013498:Suramin; D003165:Complement System Proteins; D015054:Zymosan